# FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer

Source: [What's New: Drugs RSS Feed](http://www.fda.gov/drugs/cancer-approvals/fda-approves-ensartinib-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer) · 2026-11-07 · Medicine
Page: https://themorning.science/story/fda-approves-ensartinib-for-alk-positive-locally-advanced-or-metastatic-non-smal-8bbc808668236836
Kind: launch · Impact: medium

## In brief

- On December 18, 2024, the FDA approved ensartinib (brand name Ensacove, from Xcovery Holdings, Inc.).
- The approval covers adults with locally advanced or metastatic ALK-positive non-small cell lung cancer who have not previously received an ALK inhibitor.
- The source is an FDA approval notice, republished in a drugs RSS feed dated 2026-11-07.

## Why it matters

It adds an oral targeted treatment option for a defined subgroup of lung cancer patients, and it is relevant to oncology researchers and clinicians tracking ALK-inhibitor therapies.

## Timeline

- 2024-12-18: FDA approves ensartinib (Ensacove) for ALK-positive NSCLC

## Coverage

- [FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer](http://www.fda.gov/drugs/cancer-approvals/fda-approves-ensartinib-alk-positive-locally-advanced-or-metastatic-non-small-cell-lung-cancer) — What's New: Drugs RSS Feed, 2026-11-07

Tags: oncology, lung cancer, alk inhibitor, fda approval, targeted therapy

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science